



IBA – ACQUISITION OF OWN SHARES

Immediate Release – September 24th, 2021

Louvain-la-Neuve, Belgium, September 24th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 11.792 IBA shares on Euronext Brussels in the period from September 17th, 2021 up to and including September 23th, 2021, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
17-09-21	1.221	20,09 €	20,00 €	20,25 €	24.524,64 €
20-09-21	4.137	19,52 €	19,22 €	19,84 €	80.738,93 €
21-09-21	300	19,77 €	19,56 €	19,90 €	5.931,03 €
22-09-21	2.538	19,51 €	19,30 €	19,78 €	49.515,62 €
23-09-21	3.596	19,93 €	19,80 €	20,00 €	71.651,02 €
TOTAL	11.792	19,70 €	19,22 €	20,25 €	232.361,24 €

The total number of shares purchased under this program therefore amounts to 208.432. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

	Shares	Voting rights
IBA Investments SCRL	51.973	51.973
IBA SA	563.178	626.547
Total - Treasury shares	615.151	678.520
Total - Issued shares	30.133.920	38.254.747
Treasury shares in %	2,04%	1,77%

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

Press Release

Regulated information



IBA is listed on the pan-European stock exchange Euronext (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

Contact person

IBA

Christian Matton,

IBA Chief Legal Officer

shareholderrelations@iba-group.com